Table 1.
Characteristics of study participants (n=39,497)
| Characteristic | IDH Absent | IDH Presenta | P |
|---|---|---|---|
| Participants | 27,212 (68.9) | 12,285 (31.1) | |
| IDH frequency (% of treatment) | Not applicable | ||
| >0 to ≤5 | 6096 (15.4) | ||
| >5 to ≤10 | 3789 (9.6) | ||
| >10 | 2400 (6.1) | ||
| Age, yr | 62.7±15.3 | 60.9±15.1 | <0.001 |
| Women | 15,564 (57.2) | 6598 (53.7) | <0.001 |
| Race/ethnicity | <0.001 | ||
| White | 12,728 (46.8) | 5459 (44.4) | |
| Black | 8302 (30.5) | 4214 (34.3) | |
| Hispanic | 4088 (15.0) | 1709 (13.9) | |
| Other/unknown | 2094 (7.7) | 903 (7.4) | |
| Cause of ESRD | 0.001 | ||
| Diabetes | 12,514 (46.0) | 6094 (49.6) | |
| Hypertension | 8434 (31.0) | 3579 (29.1) | |
| Glomerular disease | 1988 (7.3) | 860 (7.0) | |
| Other | 4276 (15.7) | 1752 (14.3) | |
| Prior transplant | 488 (1.8) | 209 (1.7) | 0.50 |
| Access type | <0.001 | ||
| Catheter | 17,216 (63.3) | 7535 (61.3) | |
| Fistula | 7442 (27.4) | 3476 (28.3) | |
| Graft | 2533 (9.3) | 1272 (10.4) | |
| Prevalent diabetesb | 18,246 (67.1) | 8691 (70.7) | <0.001 |
| Prevalent HFb | 10,871 (40.0) | 4864 (39.6) | 0.50 |
| Prevalent MIb | 6970 (25.6) | 3012 (24.5) | 0.02 |
| Prevalent atrial fibrillationb | 1733 (6.4) | 606 (4.9) | <0.001 |
| Prevalent CVDc | 2375 (8.8) | 1049 (8.6) | 0.50 |
| Uncontrolled hypertensiond | 25,725 (94.5) | 11,777 (95.9) | <0.001 |
| IDWG | |||
| Absolute (kg) | 4.15±2.44 | 4.52±2.24 | <0.001 |
| Relative ( %) | 3.11±1.80 | 3.30±1.60 | <0.001 |
Data are presented as the mean±SD or n (%). IDH, intradialytic hypotension; HF, heart failure; MI, myocardial infarction; CVD, cerebrovascular disease; IDWG, interdialytic weight gain; CMS, US Centers for Medicare and Medicaid Services; EMR, electronic medical record.
IDH is defined as one or more episodes during which systolic BP fell by at least 20 mmHg (predialysis to nadir intradialytic) accompanied by at least two responsive measures (premature cessation of dialysis, administration of saline, reduction in ultrafiltration rate, reduction in blood flow rate) over the period dialysis day 91 through dialysis day 180.
Defined based on CMS Medical Evidence Form 2728 data, claims (one inpatient or two outpatient), or DaVita EMR records before dialysis day 180.
Defined based on CMS Medical Evidence Form 2728 data, claims (one inpatient or two outpatient), or DaVita EMR record before dialysis day 180. Includes ischemic stroke, hemorrhagic stroke, and transient ischemic attack.
Defined as mean predialysis BP>140/90 mmHg or postdialysis BP>130/85 mmHg during the exposure assessment period (dialysis days 91–180).